ERBB2 and gastric cancer: Similarly to the findings from TCGA, in a series of intestinal type gastric cancers, HER2 over-expression was observed more often (50% of cases) in CDX2-positive cases than in CDX2-negative cases, where HER2 over-expression was only present in 1 of 15 (6.7%) of patients (p = 0.009) [34].